Intestinal metastasis from breast cancer: Presentation, treatment and survival from a systematic literature review

Table 1 Demographic and clinical data of patients with intestinal metastasis from breast cancer

	n (%)	Median (range)
Year of publication
< 2000	5 (5.8)
2001-2005	12 (13.9)
2006–2010	18 (20.9)
2011-2015	36 (41.8)
> 2016	15 (17.4)
Age		61 (31-88)
Gender
Female	94 (97.9)
Male	2 (2.1)
Breast cancer histology
Lobular carcinoma	56(58.3)
Ductal carcinoma	17 (17.7)
Phyllodes tumor	3 (0.3)
Tubular carcinoma	1 (0.1)
Mixed histology	6 (0.6)
Unknown	13 (13.5)
Time of the diagnosis
After the diagnosis of breast cancer	59 (61.4)
Concomitant	20 (20.8)
Before	1 (0.2)
Unknown	16 (16.6)1
Time after the diagnosis of breast cancer (yr)		7.2 (3 mo-25 yr)
Clinical presentation or main symptom at diagnosis
Bowel obstruction	39 (40.6)
Rectal bleeding	10 (10.4)
Perforation	2 (2)
Abdominal pain	20 (20.8)
Change in bowel habit	9 (9.3%)
Incidental	12 (12.5)
Unknown	4 (4.1)
Site of metastatization
Colon	45 (46.8)
Small bowel	43 (44.8)
Colon and small bowel	4 (4)
Anus	4 (4)
Diagnostic tool for the detection of the metastasis
Endoscopy (EGDS or colonscopy or VCE)	54 (56.2)
Radiography (CT scan, MRI, barium enema, PET)	82 (85.4)
Unknown	12 (12.5)
Treatment
Surgery and medical therapy	69/96 (71.8)
Hormone therapy and/or chemotherapy	18/96 (18.7)
Survival after the diagnosis of metastasis (yr)2		12 (1 mo-7 yr)

¹In one case the primary tumor remained occult.

²Available for 46 patients. EGDS: Esophago-gastro-duodenoscopy; VCE: Video capsule endoscopy; CT: Computed tomography; MRI: Magnetic resonance imaging; PET: Positron emission tomography.